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Abstract
The international Trial to Reduce IDDM in the Genetically at Risk (TRIGR) tested the 
hypothesis whether extensively hydrolyzed casein- based versus regular cow's milk- 
based infant formula reduces the risk of type 1 diabetes. We describe dietary compli-
ance in the trial in terms of study formula intake, feeding of nonrecommended foods, 
and serum cow's milk antibody concentration reflecting intake of cow's milk protein 
among 2,159 eligible newborn infants with a biological first- degree relative affected 
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1  | INTRODUC TION
Type 1 diabetes is one of the most common chronic diseases of 
childhood with an increasing incidence around the world (Patterson 
et al., 2019). The etiology is complex and involves a genetic pre-
disposition with suspected environmental triggers associated with 
autoimmune destruction of insulin- producing beta cells (Virtanen 
& Knip, 2003). Certain dietary factors, along with viral infections, 
are among the main suspects in the etiology of type 1 diabetes 
(Virtanen, 2016). Of the dietary factors, early feeding of cow's 
milk proteins has received much research attention with inconsist-
ent evidence from both prospective cohorts and randomized trials 
(Hummel et al., 2017; Knip et al., 2010, 2014; Vaarala et al., 2012; 
Virtanen, 2016; Writing Group for the TRIGR Study Group 
et al., 2018). Human studies are mostly observational and therefore 
confounded by issues such as breastfeeding rates and choices and 
selection bias. The Trial to Reduce IDDM in the Genetically at Risk 
(TRIGR) study reported that the cumulative incidence of diabetes- 
associated autoantibodies and type 1 diabetes in children with a 
first- degree relative with type 1 diabetes and a risk- associated HLA 
genotype did not differ in children weaned to an extensively hydro-
lyzed casein formula and one containing intact cow's milk proteins 
(Writing Group for the TRIGR Study Group et al., 2018).
TRIGR is a randomized controlled trial launched to determine 
whether weaning to extensively hydrolyzed infant formula com-
pared to one containing intact cow's milk proteins given during the 
first 6– 8 months of life would prevent type 1 diabetes in genetically 
susceptible children (Knip et al., 2014; TRIGR Study Group, 2007; 
Åkerblom et al., 2011; Writing Group for the TRIGR Study Group 
et al., 2018). It is the first nutritional full- scale randomized trial for 
prevention of type 1 diabetes. In this study, dairy foods were also 
to be avoided in the intervention period. Compliance with a dietary 
intervention and evaluation of variables associated with high com-
pliance is essential factors to assess in a nutrition intervention trial. 
Excessive noncompliance can not only result in reduced statistical 
power to detect significant associations but also limit the ability to 
accurately interpret study results. In a pilot of the current study, very 
good compliance was observed: A majority of the infants (84%) were 
exposed to study formula for at least 2 months and the levels of 
cow's milk protein antibodies reflected very well cow's milk protein 
intake (Virtanen et al., 2011; Yang et al., 2016) examined compliance 
with the completion of food records in a large cohort of children in 
and Human Development and the Special 
Statutory Funding Program for Type 
1 Diabetes Research administered by 
the National Institute of Diabetes and 
Digestive and Kidney Diseases, National 
Institutes of Health (The content is 
solely the responsibility of the authors 
and does not necessarily represent the 
official views of the National Institutes 
of Health), Canadian Institutes of Health 
Research, the Juvenile Diabetes Research 
Foundation International, the Commission 
of the European Communities (specific 
RTD programme “Quality of Life and 
management of Living Resources”, contract 
number QLK1- 2002- 00372 "Diabetes 
Prevention." It does not reflect its views 
and in no way anticipates the Commission's 
future policy in this area.) and the EFSD/
JDRF/Novo Nordisk Focused Research 
Grant. The study formulas were provided 
free of charge by Mead Johnson Nutrition
by type 1 diabetes and with HLA- conferred susceptibility to type 1 diabetes. The 
participating infants were introduced to the study formula feeding at the median age 
of 15 days with a median duration of study formula use of 63 days. During the inter-
vention, 80% of the infants received study formula. Of these, 57% received study 
formula for at least 2 months. On average, 45.5 l of study formula were used per in-
fant. Only 13% of the population had received a nonrecommended food by the age of 
6 months. The dietary compliance was similar in the intervention and control arm. The 
reported cow's milk consumption by the families matched very well with measured 
serum casein IgA and IgG antibody concentration. To conclude, good compliance was 
observed in this randomized infant feeding trial. Compliance varied between the re-
gions and those infants who were breastfed for a longer period of time had a shorter 
exposure to the study formula. High dietary compliance in infant feeding trial is nec-
essary to allow accurate interpretation of study results.
K E Y W O R D S
infant and child nutrition, infant feeding, infant formula, nutritional interventions, randomized 
controlled trial, research methodology, type 1 diabetes
Key messages
• In the TRIGR study, the intervention was designed to 
study 2 separate groups of infants— one exposed to 
cow's milk protein and a nonexposed group in order to 
assess the effect on rates of diabetes autoimmunity and 
diabetes.
• Good dietary compliance was observed in this interna-
tional randomized infant feeding trial whether meas-
ured by exposure to the study formulas, exposure to 
nonrecommended foods or by serum cow's milk protein 
antibodies.
• Compliance varied between the regions and those in-
fants who received longer breastfeeding had a shorter 
exposure to the study formula.
     |  4223VIRTANEN ET Al.
The Environmental Determinants of Diabetes in the Young (TEDDY) 
study. Factors associated with high compliance included older ma-
ternal age and higher maternal education while poor compliance was 
observed in families who lived far from the study centers and were 
from ethnic minority groups (Yang et al., 2016).
In the current study, we evaluate the degree of compliance to 
the use of study formula and to the dietary instructions on recom-
mended and nonrecommended foods. In addition, we assess how 
the reported compliance is associated with the one measured by 
cow's milk protein antibodies. Also factors associated with the re-
ported compliance are assessed.
2  | METHODS
2.1 | Recruitment and randomization
Newborn infants with a biological first- degree relative (mother, fa-
ther, or full sibling) affected by type 1 diabetes as defined by the 
World Health Organization were invited to participate. Recruitment 
strategies have been previously described in detail (TRIGR Study 
Group, 2007). The families were recruited when the mother was in 
late pregnancy (gestational age 35 weeks or more) or within 7 days 
of delivery. Informed consent was signed by the parents or legal 
guardians of the infant. Human leukocyte antigen (HLA) genotyping 
was performed from cord blood or from a blood sample obtained 
before the age of 8 days. Infants with increased HLA- conferred 
susceptibility to type 1 diabetes were eligible to participate (TRIGR 
Study Group, 2007). Altogether 2,159 infants from 12 countries in 
Europe and from United States, Canada, and Australia born between 
May 2002 and February 2007 were included in the TRIGR study 
(Åkerblom et al., 2011). Of these infants, 1,095 were born to women 
with type 1 diabetes.
Randomization stratified by geographic area was implemented 
after 35 weeks of gestation or immediately after birth by the TRIGR 
data management unit via the TRIGR website. The TRIGR countries 
were divided into seven regions, Northern Europe (Estonia, Finland, 
and Sweden, n = 555), Central Europe I (Czech Republic, Hungary and 
Poland, n = 281) (transition economies), Central Europe II (Germany, 
Luxembourg, the Netherlands and Switzerland, n = 186), Southern 
Europe (Italy and Spain, n = 114), the United States (n = 394), Canada 
(n = 528), and Australia (n = 101). The early randomization allowed 
immediate use of study formula if breastmilk was not available. If 
supplemental feeding was needed prior to randomization either 
banked breastmilk or Nutramigen® was given. Ethical approval was 
obtained at each study center.
Exclusion criteria included multiple gestation, an older sibling al-
ready participating in TRIGR, recognizable severe illness, gestational 
age <35 weeks, age of the infant more than 7 days at randomization, 
and no HLA sample drawn before the age of 8 days. Those infants 
who had received any infant formula other than the study formula 
or Nutramigen® (Mead Johnson Nutritionals) prior to randomiza-
tion, were also excluded. Finally, families having any other reasons 
(e.g., religious, cultural, and unwillingness) to refuse feeding the in-
fant with cow's milk- based products were excluded including those 
who planned only to breastfeed without ever using formula (TRIGR 
Study Group, 2007). Recruitment and retention strategies have been 
described in detail previously (Franciscus et al., 2014). Written in-
formed consent was collected from all families, signed by the legal 
guardian of the child. The study was approved by the ethics commit-
tees of all participating centers and was conducted according to the 
standards of the Declaration of Helsinki and conforms to Directive 
2010/63/EU.
2.2 | Dietary intervention
Breastfeeding was encouraged. Infants were randomized to re-
ceive either an extensively hydrolyzed casein- based infant for-
mula (Nutramigen®) or a regular cow's milk- based infant formula 
upon weaning from breast milk or when supplemental feeding was 
needed in a double- blind fashion. Both study formulas were nutri-
tionally complete infant formulas in powder form manufactured by 
one company and provided to families free of charge (Mead Johnson 
Nutritionals). The control formula was a mixture of commercial regu-
lar cow's milk- based formula powder plus casein hydrolysate powder 
in a 4:1 ratio in order to mask the flavor and smell differences be-
tween the formulas. Formula was packaged in four different colors: 
two for test and two for control formula to aid in the blinding pro-
cess, to provide a control for randomization during data analysis, and 
help to avoid accidental mis- shipments as the families recognized 
their formula can color. Nutramigen® or banked breast milk was used 
if feeding other than breast milk was needed prior to randomization 
or in delivery hospitals if study formula was unavailable in order to 
avoid exposure to intact cow's milk proteins.
The intervention lasted until the infant was 6 months old or 
if he/she had not received study formula at least for 2 months at 
that time until the age of 7– 8 months. Families were counseled to 
avoid all other infant formulas and food products containing cow's 
milk or beef. Nutramigen® was given to infants with suspected or 
proven cow's milk allergy. The use of any other infant formula (e.g., 
soy- based ones) was discouraged, to maximize exposure to study 
formula.
During the intervention phase, four study monitors managed in-
ternational coordination between European countries and Australia, 
and within North America. Each country had at least one coordi-
nator and in case of several study centers, also a local coordinator 
in each center. Each study center had nurses and physicians with 
experience in pediatrics, diabetes, neonatology or obstetrics, labo-
ratory technicians, and during the intervention period, dietitians. In 
each country, parents were provided lists of foods with brand names 
that did not contain cow's milk protein and could be used during the 
intervention as well as lists of nonrecommended foods containing 
dairy protein. Dietary advice leaflets, manual of operations, dietary 
interview forms, and other questionnaires were translated into 11 
languages and adapted to national practices.
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Information on infant feeding was acquired from the family 
through standardized dietary interviews. Data on the frequency of 
use of several allowed and nonrecommended foods were collected 
with a validated (Vahatalo et al., 2006) food frequency questionnaire 
at several time points during the first year of life. Mothers were ad-
vised and interviewed by a dietitian/study nurse by telephone when 
the child was 2 weeks old, 1, 2, 4, and 5 months old, and by a study di-
etitian during the visits at the age of 3, 6, and 9 months. When study 
formula feeding continued after the age of 6 months, 7 and 8 month 
telephone interviews were conducted by the dietitian/study nurse. 
Study formula exposure was defined as any reported consumption 
of study formula. If the child had not received the study formula for 
at least 60 days by 6 months of age, the intervention continued until 
60 days of study formula exposure was obtained up to a maximum of 
8 months of age. Noncompliance was defined as any reported expo-
sure to nonapproved formula (anything but assigned study formula 
or Nutramigen®) or nonrecommended foods (any foods containing 
milk or beef proteins).
2.3 | Measurement of cow's milk protein antibodies
IgA and IgG antibodies to cow's milk formula, beta- lactoglobulin and 
alpha- casein, were measured from serum samples obtained from 
cord blood and at the age of 3 and 6 months by ELISA (Savilahti 
et al., 1993). Cow's milk formula IgA and IgG antibodies at the age of 
0, 3, 6, and 9 months are presented in the current article to show the 
levels in the treatment arms and by cow's milk exposure.
2.4 | Statistical methods
The change in IgA and IgG casein antibody levels from 6 to 9 months 
of age was calculated by paired t test. Factors associated with the use 
of study formula were analyzed by conditional logistic regression.
3  | RESULTS
Among the infants of the 5,156 randomized mothers, 2,159 were 
eligible (Figure 1). Drop- out from the study during the intervention 
period was small and similar in both intervention arms (control arm, 
n = 18; casein hydrolysate, n = 27).
3.1 | Rates and duration of exposure to assigned 
study formula
By the end of the intervention period, 80.4% of infants had received 
study formula and 56.7% for at least 2 months (Table 1). This did 
not differ between the intervention and control arms at 80.0% and 
80.8%, respectively. The median age at introduction of study for-
mula was 15 days, and the median duration of study formula use 
was days and did not differ between the arms. According to dietary 
reports on average 45.5 L of study, formula were used per child. The 
amount of study formula used was smaller in the casein hydrolysate 
than control arm (p =.012). At 6 months of age, fewer than 4% of 
infants were being exclusively breastfed.
During the first 3 days of life, 57.8% of the infants were exclu-
sively breastfed, 8.9% had received banked milk only, 3.5% had re-
ceived study formula only, 15.1% had received Nutramigen® only, 
0.5% had received nonrecommended infant formula only, 13.7% had 
received two or more types of feeding, and 0.5% were reported not 
to have received any oral feeding. Of those who had received sev-
eral feeding types (n = 290), 2.2% had received nonrecommended 
infant formula. As study formula feeding was not available at all the 
delivery hospitals, Nutramigen® was considered allowed feeding 
straight after delivery. The early feeding did not differ between the 
treatment arms.
There was considerable variation in study formula use between 
the regions ranging from a low of 75% in North America to 86% in 
Australia and Northern Europe (Table 1). There was some increase in 
the use of study formula by time: the proportion of infants who re-
ceived it for at least 2 months increased and the proportion of non-
users decreased by time (Appendix S1). The use of nonrecommended 
foods: cow's milk- based infant formulas and other foods containing 
cow's milk or beef was similar in the treatment arms (Appendix S2). 
By the age of 6 months, 13% and 12% of the participating children in 
the intervention and control arm, respectively, had been exposed to 
nonrecommended foods.
3.2 | Exposure to nonrecommended 
formula and foods
Exposure to Nutramigen® was mostly restricted to the infants 
with proven or suspected study formula intolerance (data not 
shown). The only exception was when Nutramigen® was given at 
the delivery hospital when breast milk or study formula was not 
available. Study formula intolerance was equally often suspected 
among children in the casein hydrolysate and control arms (data 
not shown). The cumulative incidence by the age of 6 months was 
in Central European countries I 1.4%, Southern European coun-
tries 1.9%, Central European countries II 2.2%, Northern European 
countries 3.8%, Canada 6.7%, Australia 7.0%, and in the United 
States 11.2%.
In the casein hydrolysate arm, 80.0% used the study formula 
during the intervention (Table 1) and most infants were reported 
to be unexposed to bovine protein at all the visits/calls (Figure 2a). 
Exposure to cow's milk proteins varied from 2.1% at 1 month of age 
to 8.2% at 6 months, being 15.3% at 8 months for those participants 
who were still in intervention at that time. Cumulatively 84.0% were 
not exposed to foods containing bovine protein by 6 months of age 
and 81.1% by the end of the intervention.
In the control arm, 80.8% were exposed to study formula during 
the intervention (Table 1). The proportion of infants exposed to 
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bovine protein either in the form of study formula or nonrecom-
mended foods varied from 42.9% during the first 2 weeks to 64.3% 
during the 6th month of life (Figure 2b). Cumulatively, 77.2% were 
exposed to bovine protein by 6 months of life and 86.7% by the end 
of the intervention.
Median cow's milk IgA and IgG antibody concentrations by age, 
intervention arm, and cow's milk exposure are shown in Figure 3. 
Cow's milk IgA and IgG concentrations increased from birth among 
those control arm children with reported cow's milk exposure 
(Figure 3a,b). From 6 to 9 months, the levels of cow's milk IgA and 
IgG increased in all groups (p < .001).
Fifty- seven percent of the infants were exposed to study for-
mula for at least 2 months. Of the different sociodemographic and 
clinical factors studied only country and duration of breastfeeding 
were associated with at least 2 months of use of study formula in 
the model adjusted additionally for maternal age, education and 
type 1 diabetes, and sex of the child (Table 2). Being from Southern 
European countries, Canada and the United States compared to 
Northern European countries and being breastfed at least 6 months 
were associated with less compliance with at least 2 months study 
formula use (Table 2).
4  | DISCUSSION
In the TRIGR study, the intervention was designed to study 2 sepa-
rate groups of infants— one exposed to cow's milk protein and a 
nonexposed group in order to assess the effect on rates of diabe-
tes autoimmunity and diabetes. Implementing a dietary intervention 
that is maintained over 6– 8 months when the dietary component 
of interest (cow's milk protein) is very common is challenging. This 
report shows that such an intervention can be maintained with rela-
tively good success. There are two main areas of interest in an inter-
vention such as this. The first is cooperation in use of and exposure 
to the randomized study formula for sufficient duration. The second 
issue is compliance to the list of nonapproved formulae and foods. 
In our study, these exposures were low but increased with age of 
the infant. We have shown that good success can be obtained in a 
complex dietary intervention such as this.
Cooperation in use of the study formula, after breastfeed-
ing, was high at 80.4% with 56.7% using study formula for at least 
2 months by the end of the intervention. The intervention and con-
trol arms were similar regarding study formula use. The only excep-
tion was the slightly lower reported amount of study formula used 
F I G U R E  1   Flow chart of the trial to 
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by the intervention than control arm participants. In the current 
study, extensively hydrolyzed infant formula was used as the inter-
vention tool to avoid exposure to intact cow's milk proteins. The cu-
mulative proportion of infants not exposed to cow's milk proteins 
was 81% in the hydrolysate arm and the cumulative proportion of 
infants exposed to it was 81% in the control arm. This contrast in 
the exposures can be considered relatively good. Our measurement 
of antibodies to supplement the dietary interviews shows that the 
information reported by the families appeared to be reliable given 
that the reported cow's milk consumption was consistent with the 
measured casein IgA and IgG antibody concentration in serum. 
Breastfeeding for at least 6 months and being from Southern Europe 
or North America were associated with lower rates of exposure to 
study formula for at least 2 months.
In the hydrolysate study formula arm, unintended exposure to 
cow's milk proteins was very low: varying from 2% at 1 month of age 
to 8% at 6 months, and being 15% at 8 months for those participants 
who were still in the intervention. Exposure to nonapproved formula 
and foods was similarly low in the control arm (0% at 1 month, 2% 
at 6 months, and 8% at 8 months). The dietary interview forms used 
were validated (Vahatalo et al., 2006) and translated into all the lan-
guages of the study countries making it likely that data collected re-
garding noncompliance is complete.
The drop- out rates by the age of 2 years in infant feeding trials using 
hydrolyzed and long- chain polyunsaturated fatty acid- containing 
formulas have varied between 16% and 30% (Kalliomaki et al., 2001; 
Makrides et al., 1999; Mallet & Henocq, 1992; Marini et al., 1996; 
Zeiger et al., 1989). In infant feeding trials, relatively good dietary 
compliance has been observed. In a Danish allergy avoidance study, 
6.2% of the 550 infants received another formula than originally 
randomized to (Halken et al., 2000). In a Swiss allergy prevention 
study, dietary noncompliance rate was 8.4% including the use of 
other infant formulas and weaning foods than recommended (Exl 
et al., 2000). In a German study on allergy prevention, of the 2,252 
infants randomized to one of the four formulas, 58% received the 
study formula and 11% made deviations in the advised diet (von Berg 
et al., 2003). In another German study, Schoetzau et al. (2002) ex-
amined maternal compliance with nutritional recommendations in an 
allergy prevention trial and reported factors that influenced compli-
ance. The intervention was similar to the TRIGR trial in that families 
were advised to use the study formula if breastfeeding was not pos-
sible and to avoid the introduction of solid foods before 4 months 
of age. The authors reported a drop- out rate of 13.5% during the 
first year of life and a high compliance (defined as completion of all 
infant diaries and adherence to all nutritional recommendations) rate 
of 83.4% between weeks 1 and 16. In comparison, the TRIGR study 
observed a 3% drop- out rate at 1 year and had an 80.4% compliance 
rate at the completion of the intervention.
Compared to the previous TRIGR pilot study, a smaller proportion 
of the infants received study formula, for example, the proportion 
TA B L E  1   Study formula (SF) use by region: proportion of users, median (interquartile range, IQ) age at introduction and duration of use 
and mean amount of reported amount of study formula used
Regiona 
HLA eligible 
randomized SF users SF use >2 months
Age at SF 
introduction (days) SF duration (days)
Amount of 
SF used (l)
N N % N % Median IQ range Median IQ range Mean
Australia 101 87 86.1 70 69.3 49 8– 168 63 42– 112 40.2
Canada 528 399 75.6 287 54.4 16 5– 63 63 2– 161 55.9
Central Europe I 281 236 84.0 170 60.5 31 4– 168 63 21– 119 40.7
Central Europe II 186 147 79.0 111 59.7 35 11– 168 63 7– 140 45.4
Northern Europe 555 481 86.7 332 59.8 8 3– 84 63 21– 126 35.4
Southern Europe 114 91 79.8 60 52.6 10 3– 105 67 2– 154 50.3
United States 394 295 74.9 194 49.2 16 6– 60 56 2– 154 49.2
Hydrolysate arm 1,081 865 80.0 595 55.0 16 4– 112 63 2– 126 42.3
Control arm 1,078 871 80.8 629 58.4 15 4– 84 63 7– 154 48.7
All 2,159 1,736 80.4 1,224 56.7 15 4– 98 63 7– 147 45.5
aCentral Europe I includes Czech Republic, Hungary, and Poland; Central Europe II includes Germany, Luxembourg, Netherlands, and Switzerland; 
Northern Europe includes Estonia, Finland, and Sweden; and Southern Europe includes Italy and Spain.
F I G U R E  2   (a) Hydrolysate arm: the proportion (%) of children by type of feeding at the time of each interview. All of the categories may 
include breast milk. All of the children followed for at least 6 months are included (N = 1,054). The 7 and 8 month interview included only 
children who continued in the intervention up to that time: 558 and 498 children, respectively. (b) Control arm: the proportion (%) of children 
by type of feeding at the time of each interview. All the categories may include breast milk. All the children followed up at least for 6 months 
are included (N = 1,056). The 7 and 8 month interview included only children who continued in the intervention up to that time: 512 and 446 
children, respectively
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of infants with at least 2 months study formula exposure was 57% 
in the current study compared to 84% in the pilot study (Virtanen 
et al., 2011). In the current study, the introduction of study formula 
happened earlier (median 2 weeks of age compared to 2 months 
in the pilot) and the duration of observed study formula use was 
shorter (median 2 months versus 4 months, respectively). The dif-
ference in the length of the study formula use between the studies 
was partly explained by the fact that longer than recommended use 
of study formula was rather common in the pilot study, 33% of the 
infants receiving study formula longer than recommended (Virtanen 
et al., 2011). The reported proportion of families who deviated from 
the recommended diet by giving cow's milk- based infant formulas 
other than the study formula and/or other nonrecommended foods 
containing cow's milk or beef were similarly moderate in the current 
and pilot studies (18% in both).
There are a number of factors in this study that may have led to 
this degree of success in maintaining separation between the study 
arms. The study had a rigorous double- blind randomized trial design. 
Blinding was facilitated by the addition of 20% of casein hydroly-
sate also to the control formula, so the study formulas could not be 
differentiated by taste or smell. The families were contacted fre-
quently during the intervention and the drop- out up was small. The 
F I G U R E  3   Median levels of (a) cow's 
milk IgA antibodies and (b) cow's milk IgG 
antibodies by age, intervention arm, and 
cow's milk (CM) exposure status
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availability of national and international coordinators (some of them 
nutritionists) and dietitians, helped to maintain regular training of 
the personnel, coordination of the training between the regions and 
rapid responses to queries from the sites (Franciscus et al., 2014). A 
manual of operations contained detailed description of study proce-
dures including recruitment, training, advising of the families, advice 
material, forms, and study conduct. We have shown earlier that the 
intervention did not adversely affect breastfeeding habits (Sorkio 
et al., 2010). It could also be that the families who knew the child's 
HLA risk invested in the study demands.
This study has several limitations. Although our retention rates 
exceeded planning parameters and the amount of missing infor-
mation was very low, there is the possibility that participation in 
a nutrition intervention trial influenced families’ feeding choices. 
Compliance rates may also have been influenced by confounding 
factors that were not observed. Given the inclusion and exclusion 
criteria for the TRIGR study, the results may not be generalizable 
to children without increased HLA- conferred susceptibility for T1D.
The cumulative proportion of infants with suspected cow's milk 
intolerance in the current study (approximately 5%– 6% by the age 
of 8 months) was clearly above expected levels of 2%– 3% of infants 
based on strict diagnostic criteria of cow's milk allergy in developed 
countries (Host & Halken, 2014). Further, unexpectedly, it did not 
differ between the intervention arms. The method of measurement 
of intolerance used in the TRIGR centers was mainly open challenge 
test either at clinic or at home, but some families were unwilling to 
participate in the challenge.
In the TRIGR pilot study, the use of extensively hydrolyzed in-
fant formula decreased the incidence of islet cell autoantibodies, 
whereas in the current study no effect on islet autoimmunity was 
seen (Knip et al., 2010, 2014). The earlier and smaller exposure to 
study formulas in the current than in the pilot study needs to be 
considered as one possible explanation when interpreting the incon-
sistent findings of the two studies.
To conclude, good dietary compliance was observed in an inter-
national randomized infant feeding trial whether measured by ex-
posure to the study formulas, exposure to nonrecommended foods 
or by cow's milk protein antibodies. Compliance varied between the 
regions and those infants who received longer breastfeeding had a 
shorter exposure to the study formula.
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